2 active not recruiting, 2 terminated, 1 recruiting, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Cellectis S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma UCART20x22, CLLS52 - B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 / Phase 2 | Recruiting | Cellectis S.A. | 80 | 2022-11-01 | 2025-08-24 |
| Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) UCARTCS1A - Relapsed/Refractory Multiple Myeloma | Phase 1 | Terminated | Cellectis S.A. | 11 | 2019-11-21 | 2023-09-22 |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) UCART22, CLLS52 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Cellectis S.A. | 45 | 2019-10-14 | 2026-11-09 |
| Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia UCART123 - Acute Myeloid Leukaemia | Phase 1 | Withdrawn | Cellectis S.A. | 2019-07-11 | 2020-07-14 | |
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN UCART123 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 | Terminated | Cellectis S.A. | 1 | 2017-06-28 | 2019-07-31 |
| Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia UCART123v1.2 - Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | Cellectis S.A. | 29 | 2017-06-19 | 2025-08-07 |
Leukemia, Myeloid, Acute (2) · Recurrence (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1)
Alemtuzumab (2)
United States (5) · France (2) · Spain (1)
Gail Roboz, Dr (1) · Ghulam Mufti, Pr (1) · Ioana Kloos, MD (1) · Jeremy Abramson, MD (1) · Nitin Jain, MD (1)